drugset / Trial / NCT05622318
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label phase 2 study designed to explore the efficacy and safety of low-dose PTCy-ruxolitinib GVHD prophylaxis in older adults undergoing allogeneic HCT with a matched sibling or unrelated donor with a peripheral blood stem cell graft.
Timeline
- Start
- 2023-08-29
- Primary completion
- 2026-07
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 25 mg/kg | Intravenous |
| Subject | Ruxolitinib | Small molecule | 5 mg | — |
| Background | Mycophenolate Mofetil | Small molecule | 15 mg/kg | — |
| Background | Tacrolimus | Small molecule | — | Oral |